questionsmedicales.fr
Facteurs biologiques
Antigènes
Antigènes thymo-indépendants
Antigènes thymo-indépendants : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Marqueurs immunologiques
Lymphocytes B
Symptômes
5
Symptômes
Réponse immunitaire
Réponse humorale
Anticorps
Prévention
5
Système immunitaire
Nutrition
Traitements
5
Immunomodulateurs
Réponse immunitaire
Antihistaminiques
Corticostéroïdes
Complications
5
Maladies auto-immunes
Lymphocytes B
Choc anaphylactique
Allergies
Suivi médical
Complications
Facteurs de risque
5
Immunodépression
Facteurs de risque
Antécédents familiaux
Allergies
Maladies chroniques
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigènes thymo-indépendants : Questions médicales les plus fréquentes",
"headline": "Antigènes thymo-indépendants : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigènes thymo-indépendants : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-04",
"dateModified": "2025-04-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigènes thymo-indépendants"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes",
"url": "https://questionsmedicales.fr/mesh/D000941",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes",
"code": {
"@type": "MedicalCode",
"code": "D000941",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigènes thymo-indépendants",
"alternateName": "Antigens, T-Independent",
"code": {
"@type": "MedicalCode",
"code": "D000955",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Shannon L Maude",
"url": "https://questionsmedicales.fr/author/Shannon%20L%20Maude",
"affiliation": {
"@type": "Organization",
"name": "Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Saar Gill",
"url": "https://questionsmedicales.fr/author/Saar%20Gill",
"affiliation": {
"@type": "Organization",
"name": "Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Alok V Joglekar",
"url": "https://questionsmedicales.fr/author/Alok%20V%20Joglekar",
"affiliation": {
"@type": "Organization",
"name": "Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. joglekar@pitt.edu."
}
},
{
"@type": "Person",
"name": "Guideng Li",
"url": "https://questionsmedicales.fr/author/Guideng%20Li",
"affiliation": {
"@type": "Organization",
"name": "Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. guidengl_ism@163.com."
}
},
{
"@type": "Person",
"name": "Noémie Paillon",
"url": "https://questionsmedicales.fr/author/No%C3%A9mie%20Paillon",
"affiliation": {
"@type": "Organization",
"name": "Institute Curie, Université PSL, U932 INSERM, Integrative Analysis of T cell Activation Team, Paris, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap levels in myeloproliferative neoplasms.",
"datePublished": "2023-05-22",
"url": "https://questionsmedicales.fr/article/37211985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bjh.18845"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pharmacodynamic of Recombinant Human Interferon Alpha-2b Nasal Drops and Effective Prophylaxis Against SARS-COV-2 Infection.",
"datePublished": "2024-04-10",
"url": "https://questionsmedicales.fr/article/38597374",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1089/jir.2023.0193"
}
},
{
"@type": "ScholarlyArticle",
"name": "Adjuvant Topical Interferon Alpha 2b for the Treatment of Monkeypox Ocular Manifestations.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37643461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003360"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pegylated Interferon Alpha 2a for the Treatment of Ocular Surface Squamous Neoplasia.",
"datePublished": "2022-07-04",
"url": "https://questionsmedicales.fr/article/36107845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/ICO.0000000000003086"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.",
"datePublished": "2022-09-21",
"url": "https://questionsmedicales.fr/article/36131486",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10781552221125763"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes thymo-indépendants",
"item": "https://questionsmedicales.fr/mesh/D000955"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigènes thymo-indépendants - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigènes thymo-indépendants",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-30",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigènes thymo-indépendants",
"description": "Comment identifier un antigène thymo-indépendant ?\nQuels tests sont utilisés pour évaluer la réponse immunitaire ?\nLes antigènes thymo-indépendants sont-ils visibles sur des biopsies ?\nPeut-on mesurer les niveaux d'anticorps spécifiques ?\nQuels marqueurs immunologiques sont associés ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigènes thymo-indépendants",
"description": "Quels symptômes indiquent une réponse immunitaire ?\nLes antigènes thymo-indépendants causent-ils des allergies ?\nY a-t-il des signes d'infection associés ?\nComment se manifeste une réponse humorale ?\nLes symptômes varient-ils selon l'antigène ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigènes thymo-indépendants",
"description": "Comment prévenir les infections liées aux antigènes ?\nLes mesures d'hygiène sont-elles efficaces ?\nFaut-il éviter certains aliments ?\nLes vaccinations sont-elles recommandées ?\nComment renforcer le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigènes thymo-indépendants",
"description": "Quels traitements sont disponibles pour les infections ?\nPeut-on utiliser des immunomodulateurs ?\nLes vaccins sont-ils efficaces contre ces antigènes ?\nComment traiter les réactions allergiques ?\nY a-t-il des traitements préventifs ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigènes thymo-indépendants",
"description": "Quelles complications peuvent survenir ?\nLes antigènes peuvent-ils causer des maladies auto-immunes ?\nY a-t-il des risques de choc anaphylactique ?\nComment gérer les complications immunitaires ?\nLes complications sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigènes thymo-indépendants",
"description": "Quels facteurs augmentent le risque d'infection ?\nL'âge influence-t-il la réponse immunitaire ?\nLes antécédents familiaux jouent-ils un rôle ?\nLe mode de vie affecte-t-il l'immunité ?\nLes maladies chroniques sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D000955?mesh_terms=Interferon+alpha-2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un antigène thymo-indépendant ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunologiques comme l'ELISA peuvent détecter ces antigènes."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la réponse immunitaire ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de prolifération des lymphocytes B et les dosages d'anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Les antigènes thymo-indépendants sont-ils visibles sur des biopsies ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, ils ne sont pas directement visibles, mais leur effet peut être évalué par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer les niveaux d'anticorps spécifiques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests sérologiques peuvent mesurer les anticorps contre ces antigènes."
}
},
{
"@type": "Question",
"name": "Quels marqueurs immunologiques sont associés ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme CD19 et CD20 sont souvent utilisés pour évaluer les lymphocytes B."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réponse immunitaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fièvre, la fatigue et des douleurs peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les antigènes thymo-indépendants causent-ils des allergies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des réactions allergiques, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'infection associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des signes comme rougeurs ou gonflements peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une réponse humorale ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des anticorps spécifiques dans le sang est un signe clé."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'antigène ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de l'antigène et de l'individu."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections liées aux antigènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir une bonne hygiène et se faire vacciner sont des mesures clés."
}
},
{
"@type": "Question",
"name": "Les mesures d'hygiène sont-elles efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le lavage des mains et la désinfection réduisent le risque d'infection."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les aliments allergènes peut prévenir des réactions indésirables."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent prévenir certaines infections associées aux antigènes."
}
},
{
"@type": "Question",
"name": "Comment renforcer le système immunitaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice et le sommeil adéquat aident à renforcer l'immunité."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les infections ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antibiotiques et les antiviraux sont souvent utilisés selon l'infection."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser des immunomodulateurs ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des immunomodulateurs peuvent aider à réguler la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "Les vaccins sont-ils efficaces contre ces antigènes ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains vaccins ciblent des antigènes thymo-indépendants pour renforcer l'immunité."
}
},
{
"@type": "Question",
"name": "Comment traiter les réactions allergiques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antihistaminiques et les corticostéroïdes sont souvent prescrits."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccins et des traitements prophylactiques peuvent réduire les risques d'infection."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes et des allergies sévères peuvent être des complications."
}
},
{
"@type": "Question",
"name": "Les antigènes peuvent-ils causer des maladies auto-immunes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une activation inappropriée des lymphocytes B peut mener à des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de choc anaphylactique ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réactions allergiques sévères peuvent entraîner un choc anaphylactique."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications immunitaires ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier et des traitements appropriés sont essentiels."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles varient selon l'individu et le type d'antigène, mais peuvent être sérieuses."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunodépression, le stress et une mauvaise hygiène augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la réponse immunitaire ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées ont une réponse immunitaire plus faible."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il l'immunité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme, l'alcool et le manque d'exercice peuvent affaiblir l'immunité."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète ou l'asthme peuvent augmenter le risque d'infection."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 29/04/2025
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
3 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
3 publications dans cette catégorie
Affiliations :
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. joglekar@pitt.edu.
Center for Systems Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. joglekar@pitt.edu.
Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. joglekar@pitt.edu.
Publications dans "Antigènes thymo-indépendants" :
3 publications dans cette catégorie
Affiliations :
Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. guidengl_ism@163.com.
Suzhou Institute of Systems Medicine, Suzhou, China. guidengl_ism@163.com.
Key Laboratory of Synthetic Biology Regulatory Element, Chinese Academy of Medical Sciences, Beijing, China. guidengl_ism@163.com.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Institute Curie, Université PSL, U932 INSERM, Integrative Analysis of T cell Activation Team, Paris, France.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Institute Curie, Université PSL, U932 INSERM, Integrative Analysis of T cell Activation Team, Paris, France.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Apitope International NV, Diepenbeek, Belgium.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. nathan.singh@wustl.edu.
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. nathan.singh@wustl.edu.
Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA. nathan.singh@wustl.edu.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Penn Institute for Biomedical Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. mruella@upenn.edu.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Animal Tumor Models, Frontiers Science Center for Disease-Related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
Publications dans "Antigènes thymo-indépendants" :
2 publications dans cette catégorie
Affiliations :
Department of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Publications dans "Antigènes thymo-indépendants" :
Neutrophil extracellular traps (NETs) may play a pathogenic role in the thrombosis associated with myeloproliferative neoplasms (MPNs). We measured serum NET levels in 128 pretreatment samples from pa...
The recombinant human interferon alpha-2b (IFN-α2b) nasal drop formulation (Nasalferon) was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years of age received 0.5 millio...
The aim of this study was to report a case of ocular Mpox that responded favorably to treatment with topical interferon and oral doxycycline....
This is a case report of a previously healthy 24-year-old woman who developed a pustular rash, headache, fever, arthralgia, sore throat, and asthenia 3 weeks before attending to our clinic. Her main c...
Mpox with ocular manifestations diagnosis was confirmed by real-time quantitative reverse transcription polymerase chain reaction assay (qRT-PCR) testing; samples were taken from corneal, conjunctival...
Alternative and efficacious treatment options for Mpox ocular manifestations are needed to prevent further disease progression and sequelae in countries with no access to the gold-standard therapy. To...
The purpose of this study was to introduce the initial experience in the use of topical pegylated interferon alpha 2a (PegIFN-α-2a) for ocular surface squamous neoplasia (OSSN)....
A retrospective medical record review of 8 eyes of 8 patients diagnosed with OSSN and treated with PegIFN-α-2a was performed. All cases were diagnosed of noninvasive OSSN both clinically and histologi...
In all 8 cases, topical PegIFN-α-2a was well-tolerated and did not lead to discomfort or any adverse side effects. It resulted in reduction in lesion size and extent in all cases and complete resoluti...
Topical PegIFN-α-2a might be an effective and safe treatment option for noninvasive OSSN....
To report the efficacy and safety of 5-fluorouracil as the second line of treatment for two cases of conjunctival intraepithelial neoplasia refractive to topical interferon alpha-2b....
In the first case, a 77-year-old woman was evaluated because of a fleshy vascularized lesion in the temporal conjunctiva on her right eye with leukoplakia of the corneal epithelium from 10- to 5-o'clo...
In the absence of efficacy, the treatment was then changed to topical 5-fluorouracil (1%), 4 times/day for 7 days with a time-lapse of 21 days off, which constitutes a course. Two and four courses of ...
The treatment with 5-fluorouracil is a good option as the second line of treatment for conjunctival intraepithelial neoplasia who are low-responders to interferon alpha-2b, with fewer side effects tha...
Interferon alpha-2b (IFNα-2b) is an essential cytokine widely used in hepatitis and cancer treatment. This paper presents a novel protocol for purification and efficient refolding of recombinant inter...
The best antiviral treatment for chronic hepatitis B (CHB) poses a complex challenge. The treatment effect of the combination of nucleoside analogues (NAs) and pegylated interferon alpha (PegIFN) was ...
We studied patients treated with NAs and PegIFN-2b at our institution from November 2019 to January 2022. Logistic regression identified independent factors influencing clinical cure. The predictive a...
A total of 120 patients were enrolled in the final analysis. Among the cohort of patients under study, 71 (59.1%) patients had clinical cure while 49 (40.9%) patients did not. Hepatitis B surface anti...
This study provided predictive formulas for clinical cure, offering valuable insights for CHB treatment. PegIFN and NAs exhibited efficacy. Future research that explores additional factors, such as HB...
Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is ...
Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of...
Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC...
Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN ....
Lack of appropriate process models, reliable online sensors, and process variability in bioprocess systems are poising challenges in real-time monitoring and control of critical process parameters (CP...
Recombinant interferon-α2a (IFNα2a) has been widely used in the treatment of Behcet's uveitis (BU). However, the mechanism underlying its effects remains poorly understood. In this study, we investiga...